The v4.1 rubric
These seven weighted categories describe what each review examines. No 100-point score is published until every category can be scored from verified evidence for every program; rankings follow the computed transparency index below.
| Category | Points |
|---|---|
| Pricing transparency | 20 |
| Total annual cost | 20 |
| Clinical oversight | 15 |
| Pharmacy transparency | 15 |
| Support | 10 |
| Regulatory disclosure | 10 |
| Accessibility | 10 |
| Total | 100 |
- Pricing transparency: an all-in monthly price printed before checkout, the billing basis stated, no dose-based surprises.
- Total annual cost: the 12-month cost at a maintenance dose, including membership, compared with the programs in our table.
- Clinical oversight: a named medical group or medical director, a prescriber review before dispensing, and a way to reach a clinician.
- Pharmacy transparency: the dispensing pharmacy named and its type (503A or 503B) stated, so a buyer can check the license.
- Support: stated support hours and channels, coaching or nutrition help that the program describes.
- Regulatory disclosure: plain statements that compounded drugs are not FDA-approved; no claims the labels do not support.
- Accessibility: states served, payment options (FSA/HSA, installments), and how easy it is to cancel.
Rankings and scores
Rankings follow the computed transparency index: one point for each of six checks met in full (price printed, billing basis, pharmacy named, prescriber named, cancellation terms on the page, refund terms on the page), half a point for a check met in part, scored as a share of applicable checks, with ties listed alphabetically. On reads of November 20 and 21, 2026, NexLife meets 5 of 6, Hims & Hers and Mochi Health 3.5, Found and Noom Med 2.5, Calibrate and WeightWatchers Clinic 2 of 5, Henry Meds 1.5 and Form Health 1 of 5; Ro is not ranked because its pages blocked us.
NexLife is also our editor's pick. That is an editorial selection, labelled as such wherever it appears, and kept separate from the computed order. We withdrew the fixed 94/100 v4.1 score on November 21, 2026 because four of the seven categories (clinical oversight, support, regulatory disclosure, accessibility) could not be scored from verified evidence for every program, and the July 2026 scores from our former six-criterion rubric are retired.
FDA warning letters are disclosed the same way for every program and add or subtract no points: FDA's index lists letter 730096 to NexLife (June 8, 2026) and letters 716567 and 716825 to Hims & Hers (September 9, 2025), none with a posted close-out.
Price checks on price pages
Price pages apply five checks: billed by the month, medication and care in one price, same price at every dose, no membership, and a first-party read. Market figures use the lowest all-in monthly price per program, with an annual membership divided by 12.
Sources and dates
Prices come only from the program's own pages and carry the read date. When a page cannot be read, the older figure is kept with its old date and flagged; we never estimate. Clinical statements come from FDA prescribing information and peer-reviewed trials, attributed to the trial and its estimand.
What changed
Until November 8, 2026, this page described a six-criterion rubric scored 0–10 that gave bonus points for dual 503A/503B sourcing and for physician credentials, and it listed a NexLife pharmacy network and prices that NexLife's current pages do not support. That version is retired; see corrections. Ranked results are on the rankings page and prices in the price index.